GlassScriptPhysician profile
Behzad Elahi
NPI 1932549698
$7,831.99
in general payments reported to CMS, 2019-2025
14 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $24.75 · 2021: $829 · 2022: $3,143 · 2023: $822 · 2024: $2,603 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,200 · Food and Beverage: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,200.00 |
| Food and Beverage | $1,510.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,469.34 | 2023-2025 | |
| Abbott Laboratories | $2,364.89 | 2019-2025 | Infinity |
| Boston Scientific Corporation | $1,169.82 | 2022 | |
| Medtronic, INC. | $967.68 | 2021-2025 | Activa PC, Sensight |
| Kyowa Kirin, INC. | $321.98 | 2022-2023 | Nourianz |
| Mdd US Operations, LLC | $315.71 | 2022-2025 | Gocovri, Apokyn |
| Acadia Pharmaceuticals INC | $64.17 | 2023 | Nuplazid |
| Allergan, INC. | $43.96 | 2019 | |
| Tanabe Pharma America, INC. | $25.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.75 | 2020 | |
| Lundbeck LLC | $17.36 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.55 | 2024 | Crexont |
| Saol Therapeutics INC. | $15.53 | 2019 | |
| Lilly USA, LLC | $14.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Behzad Elahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.